Free for academic non-profit institutions. Other users need a Commercial license
This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. [provided by RefSeq, Nov 2015]
VEGFA (Vascular Endothelial Growth Factor A) is a Protein Coding gene. Diseases associated with VEGFA include Microvascular Complications Of Diabetes 1 and Poems Syndrome. Among its related pathways are Cellular Senescence (REACTOME) and Hypertrophy Model. Gene Ontology (GO) annotations related to this gene include protein homodimerization activity and protein heterodimerization activity. An important paralog of this gene is PGF.
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0001968 | fibronectin binding | IDA | 14570917 |
GO:0005125 | cytokine activity | ISS | -- |
GO:0005161 | platelet-derived growth factor receptor binding | IPI | 17470632 |
GO:0005172 | vascular endothelial growth factor receptor binding | IPI | 10471394 |
GO:0005515 | protein binding | IPI | 9393862 |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0005576 | extracellular region | TAS | -- |
GO:0005615 | extracellular space | IBA,ISS | -- |
GO:0005737 | cytoplasm | IDA | 17082651 |
GO:0005913 | cell-cell adherens junction | IDA | 26598555 |
GO:0009986 | cell surface | IDA | 17470632 |
SuperPathway | Contained pathways | ||
---|---|---|---|
1 | Response to elevated platelet cytosolic Ca2+ |
.44
|
|
2 | Development VEGF signaling via VEGFR2 - generic cascades | ||
3 | VEGF Pathway (Qiagen) |
VEGF Family Ligands and Receptor Interactions
.66
VEGF Pathway
.66
|
|
4 | CDK-mediated phosphorylation and removal of Cdc6 | ||
5 | RET signaling |
GO ID | Qualified GO term | Evidence | PubMed IDs |
---|---|---|---|
GO:0000122 | negative regulation of transcription by RNA polymerase II | IDA | 18093989 |
GO:0001525 | angiogenesis | IDA,IBA | 11427521 |
GO:0001541 | ovarian follicle development | ISS | -- |
GO:0001569 | branching involved in blood vessel morphogenesis | ISS | -- |
GO:0001570 | vasculogenesis | TAS | 15015550 |